MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.85
+0.38
+3.96%
After Hours: 9.85 0 0.00% 19:59 01/17 EST
OPEN
9.37
PREV CLOSE
9.48
HIGH
10.19
LOW
9.36
VOLUME
14.20M
TURNOVER
--
52 WEEK HIGH
32.05
52 WEEK LOW
2.930
MARKET CAP
539.93M
P/E (TTM)
-1.3121
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLVS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLVS News

  • Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
  • Zacks.2d ago
  • Why This Highly Rated Biotech Stock Jumped As High As 26%
  • Investor's Business Daily.3d ago
  • FDA accepts Clovis application for new use of Rubraca; shares up 13% premarket
  • seekingalpha.3d ago
  • Here's Why Clovis Oncology Rose as Much as 25.6% Today
  • MotleyFool.com.3d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More

Webull offers Clovis Oncology Inc (CLVS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.